Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.
Faber ML, Oldham RAA, Thakur A, Rademacher MJ, Kubicka E, Dlugi TA, Gifford SA, McKillop WM, Schloemer NJ, Lum LG, Medin JA.
Faber ML, et al. Among authors: rademacher mj.
Front Immunol. 2023 Aug 14;14:1225610. doi: 10.3389/fimmu.2023.1225610. eCollection 2023.
Front Immunol. 2023.
PMID: 37646042
Free PMC article.